) --




) hit a new 52-week high Wednesday as it is currently trading at $70.09, above its previous 52-week high of $69.99 with 160,373 shares traded as of 3:51 p.m. ET. Average volume has been 291,400 shares over the past 30 days.

Gen-Probe has a market cap of $3.3 billion and is part of the


sector and

diversified services

industry. Shares are up 18.8% year to date as of the close of trading on Tuesday.

TheStreet Recommends

Gen-Probe Incorporated engages in the development, manufacture, and marketing of nucleic acid tests used primarily to diagnose human diseases and screen donated human blood in North America and internationally. The company has a P/E ratio of 31.6, equal to the average diversified services industry P/E ratio and above the S&P 500 P/E ratio of 16.7.

  • Practice your GPRO trading strategies and win cash in our stock game.

TheStreet Ratings rates Gen-Probe as a


. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, expanding profit margins, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full

Gen-Probe Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center